Observational study of Nab-paclitaxel followed by Anthracycline based regimen as preoperative chemotherapy for ER-negative resectable primary breast cancer
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000020994
- Lead Sponsor
- SHINKO HOSPITA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 40
Not provided
1)patients with previous treatment history of nab-paclitaxel 2)active double cancer (synchronous double cancer and metachronous double cancer disease-free period is within 5 years) 3)serious complications (congestiveheart failure, coronary insufficiency, heart disease such as a myocardial infarction and angina pectoris and Arrhythmia requiring treatment, history of cerebrovascular disease, gastrointestinal ulcer bleeding or requiring treatment, control bad diabetes, renal failure, active hepatitis and cirrhosis, liver failure, etc.) 4)has a fever, suspected infection 5)pleural effusion requiring treatment, pericardial effusion example 6)a clear interstitial pneumonia or pulmonary fibrosis in the chest X photos and chest CT 7)a history of drug hypersensitivity 8)a history of severe hypersensitivity for the components of the therapeutic agent (nab-paclitaxel) 9) a possibility of pregnancy and pregnancy, or breast-feeding 10)history of serious mental illness or are under treatment, patients judged that the participation in examination is difficult 11)HBs antigen-positive 12)Other cases of the physician has determined to be inappropriate as a target
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathological complete response rate
- Secondary Outcome Measures
Name Time Method